Vida Ventures (Vida), a next-generation life sciences venture firm, has closed Vida Ventures III (Vida III) on USD825 million. Vida, founded in 2017, now has over USD1.7 billion of assets under management.
Vida III will build upon the success of Vida’s first two funds and continue its investment approach of identifying and investing in transformative biomedical innovations with the potential to meaningfully impact patients. The capital was raised globally from existing and new blue-chip institutional investors, including top-tier endowments and foundations, sovereign wealth funds, pensions, financial institutions, family offices, fund-of-funds and notable individuals.
Since inception, Vida has made 30 investments in companies developing transformative therapies for difficult-to-treat indications across oncology, neurology, autoimmunity, rare genetic diseases and beyond. With experience building and scaling companies from concept to commercialization, Vida takes a hands-on approach and is deeply involved with its portfolio companies across the full life cycle of value creation.
